Editas Medicine (EDIT)

$4.54 0.07 (1.52%)

16:00 EDT EDIT Stock Quote Delayed 30 Minutes

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

By Ian Cooper, InvestorPlace Contributor Jun 26, 2024

Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024

7 Mighty Healthcare Stocks Changing the Game of Medicine

Volume:

Previous Close -

Market Cap 370.61M

PE Ratio -2.18

EPS -2.08

Volume (Avg. Vol.) 1.55M

Day's Range $4.45 - $4.63

52-Week Range $4.45 - $11.69

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

3 Stocks to Buy in the Booming Field of Gene Editing

By Chris Markoch, InvestorPlace Contributor Jan 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names

By Ian Cooper, InvestorPlace Contributor Nov 29, 2023

As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.

Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year

By Ian Cooper, InvestorPlace Contributor Nov 22, 2023

Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

By Ian Cooper, InvestorPlace Contributor Nov 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

3 Long-Term Growth Stocks Analysts Are Bullish On

By Chris Markoch, InvestorPlace Contributor Nov 16, 2023

Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

By Chris Markoch, InvestorPlace Contributor Nov 9, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

3 Gene Editing Stocks to Generate Super-Charged Gains

By Ian Cooper, InvestorPlace Contributor Oct 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Oct 17, 2023

It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?

By Samuel O'Brient, InvestorPlace Reporter Jun 6, 2023

Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.

7 Short-Squeeze Stocks Set for a May Rally

By Josh Enomoto, InvestorPlace Contributor May 22, 2023

While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

By John Blankenhorn, InvestorPlace Contributor Apr 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?

By Josh Enomoto, InvestorPlace Contributor Apr 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

By Josh Enomoto, InvestorPlace Contributor Mar 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later

By Ian Bezek, InvestorPlace Contributor Feb 2, 2023

CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

By Ian Cooper, InvestorPlace Contributor Jan 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in ten years.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 7, 2022

Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Feb 8, 2022

Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today

By Joel Baglole, InvestorPlace Contributor Dec 13, 2021

After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.

Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful

By Mark R. Hake, CFA Oct 19, 2021

EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech.

Editas Medicine (EDIT)

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024

7 Mighty Healthcare Stocks Changing the Game of Medicine

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Editas Medicine (EDIT)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

EDIT Stock Predictions, Articles, and Editas Medicine News

Subscriber Sign in